Pharmaceuticals, Biotechnology and Life Sciences
Bioparticle-based delivery system offers potential as a coronavirus therapy LOS ANGELES–(BUSINESS WIRE)–An emerging company developing biotechnology invented at UCLA is…
Mylan is potentially getting access to 14 indications after approval, as first neurotoxin formulation to be developed as a potential biosimilar product to BOTOX.
BETHESDA, Md. & AUSTIN, Texas–(BUSINESS WIRE)–Longhorn Vaccines & Diagnostics, an innovative molecular tool, assay and vaccine development company focused on…
NEW YORK–(BUSINESS WIRE)–Treadwell Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that members of…
-With More than 1.9 Million Square Feet of Greenhouses, Clever Leaves is One of the Largest Cannabis Cultivation and Extraction…
Resolution of middle ear effusion in 56% of OP0201 vs. 38% of placebo patients (p=0.07) Company engages financial advisors to…
— Important Data on Psychosocial Burden of Peanut Allergy on Children and Caregivers Also to be Presented — BRISBANE, Calif.–(BUSINESS…
AstraZeneca on Friday reported several clinical results from its studies, including Imfinzi and Enhertu, with meaningful outcomes.
Mylan said on Friday that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi’s Lantus® SoloSTAR® device patents, U.S. Patent Nos. 8,603,044, 8,992,486, and 9,526,844 unpatentable.
Analyses from KEYTRUDA Plus LENVIMA Trials to be Presented at 2020 ASCO Annual Meeting KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.–(BUSINESS…